Use of phosphorylated tau and p38gamma to treat a neurological condition

Lars Matthias Ittner (Inventor), Arne Anselm Ittner (Inventor)

Research output: Patent

Abstract

The present invention relates to a method of treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject, comprising treating the subject to: (a) promote phosphorylation of one or more amino acid residues of tau, wherein the phosphorylation of the amino acid residues causes disruption of the tau-dependent signalling complex in neurons of the subject; or (b)introduce a variant of tau that causes disruption of the tau-dependent signalling complex in neurons of the subject. The invention also relates to vectors, compositions and kits for treating or preventing a neurological condition mediated by a tau-dependent signalling complex in neurons of a subject.

Original languageEnglish
Patent numberAU2017225907
IPCA61P 25/28,A61K 38/17,A61P 9/10,A61P 25/08
Priority date1/03/17
Filing date1/03/17
Publication statusSubmitted - 8 Sep 2017

Fingerprint Dive into the research topics of 'Use of phosphorylated tau and p38gamma to treat a neurological condition'. Together they form a unique fingerprint.

Cite this